3D tissue-engineered model of Ewing's sarcoma

被引:34
作者
Lamhamedi-Cherradi, Salah-Eddine a [1 ]
Santoro, Marco [1 ,2 ,3 ]
Ramammoorthy, Vandhana [1 ]
Menegaz, Brian A. [1 ]
Bartholomeusz, Geoffrey [4 ]
Iles, Lakesla R. [4 ]
Amin, Hesham M. [5 ]
Livingston, J. Andrew [6 ]
Mikos, Antonios G. [2 ,3 ]
Ludwig, Joseph A. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr MDACC, Dept Sarcoma Med Oncol, Houston, TX 77054 USA
[2] Rice Univ, Dept Chem & Biomol Engn, Houston, TX 77005 USA
[3] Rice Univ, Dept Bioengn, Houston, TX 77005 USA
[4] MDACC, SiRNA Screen Lab, Dept Expt Therapeut, Houston, TX 77005 USA
[5] Dept Hematopathol MDACC, Houston, TX 77005 USA
[6] Div Canc Med MDACC, Houston, TX 77005 USA
关键词
Ewing's sarcoma; MCTS; 3D; Tissue-engineering; Scaffolds; ECM; Tumor model; Preclinical testing; GROWTH-FACTOR RECEPTOR; EXTRACELLULAR-MATRIX DEGRADATION; MULTICELLULAR TUMOR SPHEROIDS; MESENCHYMAL STEM-CELLS; NATURAL-KILLER-CELLS; LUNG-CANCER CELLS; IN-VITRO MODEL; ENDOTHELIAL-CELLS; GENE-EXPRESSION; LYSYL OXIDASE;
D O I
10.1016/j.addr.2014.07.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite longstanding reliance upon monolayer culture for studying cancer cells, and numerous advantages from both a practical and experimental standpoint, a growing body of evidence suggests that more complex three-dimensional (3D) models are necessary to properly mimic many of the critical hallmarks associated with the oncogenesis, maintenance and spread of Ewing's sarcoma (ES), the second most common pediatric bone tumor. And as clinicians increasingly turn to biologically-targeted therapies that exert their effects not only on the tumor cells themselves, but also on the surrounding extracellular matrix, it is especially important that preclinical models evolve in parallel to reliably measure antineoplastic effects and possible mechanisms of de novo and acquired drug resistance. Herein, we highlight a number of innovative methods used to fabricate biomimetic ES tumors, encompassing both the surrounding cellular milieu and the extracellular matrix (ECM), and suggest potential applications to advance our understanding of ES biology, preclinical drug testing, and personalized medicine. (C) 2014 The Authors. Published by Elsevier B.V.
引用
收藏
页码:155 / 171
页数:17
相关论文
共 235 条
[121]   Bioactive polymer/extracellular matrix scaffolds fabricated with a flow perfusion bioreactor for cartilage tissue engineering [J].
Liao, Jiehong ;
Guo, Xuan ;
Grande-Allen, K. Jane ;
Kasper, F. Kurtis ;
Mikos, Antonios G. .
BIOMATERIALS, 2010, 31 (34) :8911-8920
[122]   Modulation of osteogenic properties of biodegradable polymer/extracellular matrix scaffolds generated with a flow perfusion bioreactor [J].
Liao, Jiehong ;
Guo, Xuan ;
Nelson, Dan ;
Kasper, F. Kurtis ;
Mikos, Antonios G. .
ACTA BIOMATERIALIA, 2010, 6 (07) :2386-2393
[123]  
Lin P.P., 2011, MESENCHYMAL STEM CEL
[124]  
Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228
[125]   The extracellular matrix: A dynamic niche in cancer progression [J].
Lu, Pengfei ;
Weaver, Valerie M. ;
Werb, Zena .
JOURNAL OF CELL BIOLOGY, 2012, 196 (04) :395-406
[126]   Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future [J].
Ludwig, Joseph A. .
CURRENT OPINION IN ONCOLOGY, 2008, 20 (04) :412-418
[127]   Advances in Ewing's Sarcoma Research: Where Are We Now and What Lies Ahead? [J].
Luis Ordonez, Jose ;
Osuna, Daniel ;
Herrero, David ;
de Alava, Enrique ;
Madoz-Gurpide, Juan .
CANCER RESEARCH, 2009, 69 (18) :7140-7150
[128]  
Lwing J., 1921, CA-CANCER J CLIN, V22, P95
[129]   The effect of PEGT/PBT scaffold architecture on oxygen gradients in tissue engineered cartilaginous constructs [J].
Malda, J ;
Woodfield, TBF ;
van der Vloodt, F ;
Kooy, FK ;
Martens, DE ;
Tramper, J ;
van Blitterswijk, CA ;
Riesle, J .
BIOMATERIALS, 2004, 25 (26) :5773-5780
[130]   A novel zinc finger gene is fused to EWS in small round cell tumor [J].
Mastrangelo, T ;
Modena, P ;
Tornielli, S ;
Bullrich, F ;
Testi, MA ;
Mezzelani, A ;
Radice, P ;
Azzarelli, A ;
Pilotti, S ;
Croce, CM ;
Pierotti, MA ;
Sozzi, G .
ONCOGENE, 2000, 19 (33) :3799-3804